Previously, it was shown that betahistine (a histamine H1R agonist) could act at H1R to ameliorate OLZ-induced dyslipidemia via the AMPKα-SREBP-1 and PPARα-dependent pathways in rats56. This evidence concerns the gene SREBF1 and metabolic syndrome.